Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7242793
Reference Type
Journal Article
Title
Synthetic LXR Agonist Suppresses Endogenous Cholesterol Biosynthesis and Efficiently Lowers Plasma Cholesterol
Author(s)
Pfeifer, T; Buchebner, M; Chandak, PG; Patankar, Jay; Kratzer, A; Obrowsky, S; Rechberger, GN; Kadam, RS; Kompella, UB; Kostner, GM; Kratky, D; Levak-Frank, S
Year
2011
Is Peer Reviewed?
1
Journal
Current Pharmaceutical Biotechnology
ISSN:
1389-2010
EISSN:
1873-4316
Volume
12
Issue
2
Page Numbers
285-292
Language
English
PMID
21190543
DOI
10.2174/138920111794295774
Web of Science Id
WOS:000286876200019
URL
http://openurl.ingenta.com/content/xref?genre=article&issn=1389-2010&volume=12&issue=2&spage=285
Exit
Relationship(s)
has retraction
11962326
(vol 12, pg 285, 2011)
Abstract
The liver X receptors (LXRs) are key regulators of genes involved in cholesterol homeostasis. Natural ligands and activators of LXRs are oxysterols. Numerous steroidal and non-steroidal synthetic LXR ligands are under development as potential drugs for individuals suffering from lipid disorders. N,N-dimethyl-3β-hydroxycholenamide (DMHCA) is a steroidal ligand of LXRs that exerts anti-atherogenic effects in apolipoprotein E-deficient mice without causing negative side effects such as liver steatosis or hypertriglyceridemia. In this report, we investigated the consequences of DMHCA treatment on cholesterol homeostasis in vivo and in vitro. Despite its hydrophobicity, DMHCA is readily absorbed by C57BL/6 mice and taken up by intestinal cells, the lung, heart and kidneys, but is undetectable in the brain. DMHCA significantly reduces cholesterol absorption and uptake in duodenum and jejunum of the small intestine and in turn leads to a reduction of plasma cholesterol by 24%. The most striking finding of this study is that DMHCA inhibited the enzyme 3β-hydroxysterol-Δ24-reductase resulting in an accumulation of desmosterol in the plasma and in feces. Thus, the reduction of plasma cholesterol was due to a block in the final step of cholesterol biosynthesis. Taken together, DMHCA is an interesting compound with properties distinct from other LXR ligands and might be used to study desmosterol-mediated effects in cells and tissues.
Keywords
Cholesterol absorption; cholesterol biosynthesis; desmosterol; DHCR24; DMHCA; liver X receptor
Tags
•
PFAS Universe
Data Source
Web of Science
N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxy-propan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity